BACKGROUND: Although insulin treatment confers short-term benefit in cystic fibrosis-related diabetes (CFRD), few studies have compared its long-term effect on the clinical outcome. OBJECTIVES: In this study, we aimed to investigate the long-term impact of insulin treatment on pulmonary function, nutritional status and hospital admissions in patients with CFRD. METHODS: We reviewed pulmonary function, body mass index (BMI) and hospital admissions 5 years before and 3 years after insulin therapy in 42 adult CFRD patients. RESULTS: Prior to treatment, over a period of 5 years, the annual rate of change in forced expiratory volume in 1 s (FEV(1)) was -3.2%, forced vital capacity (FVC) -2.5%, and BMI -0.07%. At treatment of CFRD (baseline), the mean FEV(1) was 51.6% predicted (range 24-96), FVC 66.4% (range 29-103) and BMI 19.5 (range 15.3-29.5). At 3 months following insulin treatment, there was a significant improvement in all parameters, which was maintained at 1 year for FEV(1) (55.1%; p < 0.002), 2 years for FVC (72.1%; p < 0.01) and at 3 years for BMI (20.4%; p < 0.002). After 3 months, FEV(1) declined at a rate similar to that before treatment (-3.2 vs. -3.1% per year; p = 0.77), such that the mean FEV(1) after treatment returned to pretreatment baseline values at 34 months. There was no difference in the number of hospital admissions with insulin treatment. CONCLUSIONS: Insulin enhances the nutritional state and temporarily improves pulmonary function in CFRD patients, on average delaying the decline in FEV(1) by 34 months. Copyright 2007 S. Karger AG, Basel.
BACKGROUND: Although insulin treatment confers short-term benefit in cystic fibrosis-related diabetes (CFRD), few studies have compared its long-term effect on the clinical outcome. OBJECTIVES: In this study, we aimed to investigate the long-term impact of insulin treatment on pulmonary function, nutritional status and hospital admissions in patients with CFRD. METHODS: We reviewed pulmonary function, body mass index (BMI) and hospital admissions 5 years before and 3 years after insulin therapy in 42 adult CFRD patients. RESULTS: Prior to treatment, over a period of 5 years, the annual rate of change in forced expiratory volume in 1 s (FEV(1)) was -3.2%, forced vital capacity (FVC) -2.5%, and BMI -0.07%. At treatment of CFRD (baseline), the mean FEV(1) was 51.6% predicted (range 24-96), FVC 66.4% (range 29-103) and BMI 19.5 (range 15.3-29.5). At 3 months following insulin treatment, there was a significant improvement in all parameters, which was maintained at 1 year for FEV(1) (55.1%; p < 0.002), 2 years for FVC (72.1%; p < 0.01) and at 3 years for BMI (20.4%; p < 0.002). After 3 months, FEV(1) declined at a rate similar to that before treatment (-3.2 vs. -3.1% per year; p = 0.77), such that the mean FEV(1) after treatment returned to pretreatment baseline values at 34 months. There was no difference in the number of hospital admissions with insulin treatment. CONCLUSIONS:Insulin enhances the nutritional state and temporarily improves pulmonary function in CFRD patients, on average delaying the decline in FEV(1) by 34 months. Copyright 2007 S. Karger AG, Basel.
Authors: Alicia K Olivier; Yaling Yi; Xingshen Sun; Hongshu Sui; Bo Liang; Shanming Hu; Weiliang Xie; John T Fisher; Nicholas W Keiser; Diana Lei; Weihong Zhou; Ziying Yan; Guiying Li; Turan I A Evans; David K Meyerholz; Kai Wang; Zoe A Stewart; Andrew W Norris; John F Engelhardt Journal: J Clin Invest Date: 2012-09-17 Impact factor: 14.808
Authors: Antoinette Moran; Dorothy Becker; Samuel J Casella; Peter A Gottlieb; M Sue Kirkman; Bruce C Marshall; Bonnie Slovis Journal: Diabetes Care Date: 2010-12 Impact factor: 19.112
Authors: Scott M Blackman; Stephanie Hsu; Lori L Vanscoy; J Michael Collaco; Sarah E Ritter; Kathleen Naughton; Garry R Cutting Journal: J Clin Endocrinol Metab Date: 2009-01-06 Impact factor: 5.958
Authors: Christine L Chan; Timothy Vigers; Laura Pyle; Philip S Zeitler; Scott D Sagel; Kristen J Nadeau Journal: J Cyst Fibros Date: 2018-03-23 Impact factor: 5.482
Authors: S M Blackman; S Hsu; S E Ritter; K M Naughton; F A Wright; M L Drumm; M R Knowles; G R Cutting Journal: Diabetologia Date: 2009-07-08 Impact factor: 10.122